Article

Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review

Headache Group-Department of Neurology, University of California, San Francisco, San Francisco, CA 94115, USA.
Cephalalgia (Impact Factor: 4.12). 02/2009; 29(5):496-508. DOI: 10.1111/j.1468-2982.2008.01800.x
Source: PubMed

ABSTRACT Lidocaine has been used in treatment of patients with refractory headache. Personal observations of neuropsychiatric toxicity in these patients led us to review our cases and the literature systematically for lidocaine side-effects, especially neuropsychiatric symptoms. In our series of 20 patients, side-effects were observed in all, the most frequent being neuropsychiatric (75%) and cardiological (50%). When reviewing published series on intravenous lidocaine use, reports of side-effects range from 0 to 100%, with neuropsychiatric symptoms being reported in 1.8-100%. Thirty-six case reports of lidocaine-induced psychiatric symptoms were also analysed. Psychiatric symptoms of toxicity were similar in most patients, despite their differing ages, pathologies, co-therapies and lidocaine dosages. In conclusion, lidocaine neuropsychiatric toxicity has a well-recognized stereotypical clinical presentation that is probably unrecognized in headache series. As lidocaine represents an emerging alternative therapy in headache, particularly in short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing, clinicians and patients should be aware of the extent of this problem.

Download full-text

Full-text

Available from: Raquel Gil-Gouveia, Aug 28, 2015
1 Follower
 · 
183 Views
  • Source
    • "Nous avons effectué la revue de l'EBM sur la lidocaïne pour le traitement des douleurs neuropathiques, essentiellement à partir de la méta-analyse de la revue Cochrane publiée en 2005, pour le traitement de la fibromyalgie et celui des céphalées chroniques quotidiennes 5—7. Cette revue de la littérature a fait apparaître la lidocaïne intraveineuse comme un traitement de deuxième ou troisième intention avec des effets indésirables potentiellement graves d'origine cardiaque et neurologique [7]. Nous avons étudié le manuel de certification de la HAS sur les différentes méthodes proposées pour la réalisation "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Since quality improvement programs are now mandatory, we decided to put it in practice in our pain day care unit. Objective To realize a quality improvement program on the clinical practices in our pain day care unit and to obtain our certification. Method (1) Plan: bibliography review, as well as a review of procedures in our pain day care unit; clinical pathway choice; (2) Do: realization from November 2007 to November 2009, with three physicians in the pilot committee; a multidisciplinary team meeting was organized to validate intravenous lidocaïne indications; creation of documents and a 10-item questionnaire; (3) Check and act: three audits were made; the health economics data was collected with our medical informatics system program. Results Between the first and last round of the audit, compliance with quality criteria increased significantly from 45–95 % to 80–100 %, depending on the item. After an initial 36 % reduction in 2008, the recruitment level at the end of the program was identical to that before program implementation. A clear increase in activity-based funding was observed at the end of the program (+77 %) for the same period. Discussion Our programme led to an improvement in practice. Financial savings resulted from activity-based costing after the creation of a “disease-related group” for refractory chronic pain but also from compensation of the initial fall in activity by a better occupancy rate in the day hospital. Conclusion The clinical pathway is a simple and effective method of optimizing clinical practices in pain clinics with the use of potential iatrogenic treatment.
    Douleurs Evaluation - Diagnostic - Traitement 06/2010; 11(3):107-115. DOI:10.1016/j.douler.2010.03.014
  • Source
    • "Owing to ubiquitous distribution of the nine known sodium channels in many tissues of the body and the essential role of these channels in the function of excitable membranes, however, recipients risk dangerous cardiac and central nervous system effects. For example, lidocaine produces cardiac arrhythmia and ataxia at the same dosages required to yield analgesia in neuropathic pain models (Challapalli et al., 2005; Gil-Gouveia and Goadsby, 2009). Potentially, these risks could be minimized by using agents that influence just a subset of sodium channel subtypes. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.
    Behavioural pharmacology 09/2009; 20(8):755-8. DOI:10.1097/FBP.0b013e3283323c90 · 2.19 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tako-tsubo cardiomyopathy is a cardiac syndrome precipitated by profound emotional stress and anxiety, particularly in middle-aged women. It presents as a mimic of acute myocardial infarction, but coronary angiography shows normal coronary arteries and a characteristic left ventriculogram resembling an "octopus pot". The condition seems to have a favourable prognosis. Initially described in Japan, and with many names in the literature, it is being increasingly recognised in the West owing to early coronary angiography and primary coronary intervention, accounting for up to 1 in 30 primary cases of angioplasty in some institutions. A typical case is described, and the clinical features, pathophysiology and management reviewed.
    Postgraduate medical journal 01/2007; 82(974):e29. DOI:10.1136/pgmj.2006.051367 · 1.55 Impact Factor
Show more